182 related articles for article (PubMed ID: 37100883)
1. Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation.
Kielbassa K; Haselager MV; Bax DJC; van Driel BF; Dubois J; Levin MD; Kersting S; Svanberg R; Niemann CU; Kater AP; Eldering E
Leukemia; 2023 Jun; 37(6):1268-1276. PubMed ID: 37100883
[TBL] [Abstract][Full Text] [Related]
2. Changes in Bcl-2 members after ibrutinib or venetoclax uncover functional hierarchy in determining resistance to venetoclax in CLL.
Haselager MV; Kielbassa K; Ter Burg J; Bax DJC; Fernandes SM; Borst J; Tam C; Forconi F; Chiodin G; Brown JR; Dubois J; Kater AP; Eldering E
Blood; 2020 Dec; 136(25):2918-2926. PubMed ID: 32603412
[TBL] [Abstract][Full Text] [Related]
3. Electron transport chain and mTOR inhibition synergistically decrease CD40 signaling and counteract venetoclax resistance in chronic lymphocytic leukemia.
Chen Z; Cretenet G; Carnazzo V; Simon-Molas H; Kater AP; Windt GJWV; Eldering E
Haematologica; 2024 Jan; 109(1):151-162. PubMed ID: 37439352
[TBL] [Abstract][Full Text] [Related]
4. BCL-2 Inhibition as Treatment for Chronic Lymphocytic Leukemia.
Perini GF; Feres CCP; Teixeira LLC; Hamerschlak N
Curr Treat Options Oncol; 2021 Jun; 22(8):66. PubMed ID: 34110507
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic Leukemia.
Cervantes-Gomez F; Lamothe B; Woyach JA; Wierda WG; Keating MJ; Balakrishnan K; Gandhi V
Clin Cancer Res; 2015 Aug; 21(16):3705-15. PubMed ID: 25829398
[TBL] [Abstract][Full Text] [Related]
6. Dichotomy in NF-kappaB signaling and chemoresistance in immunoglobulin variable heavy-chain-mutated versus unmutated CLL cells upon CD40/TLR9 triggering.
Tromp JM; Tonino SH; Elias JA; Jaspers A; Luijks DM; Kater AP; van Lier RA; van Oers MH; Eldering E
Oncogene; 2010 Sep; 29(36):5071-82. PubMed ID: 20581863
[TBL] [Abstract][Full Text] [Related]
7. Bruton's tyrosine kinase inhibition increases BCL-2 dependence and enhances sensitivity to venetoclax in chronic lymphocytic leukemia.
Deng J; Isik E; Fernandes SM; Brown JR; Letai A; Davids MS
Leukemia; 2017 Oct; 31(10):2075-2084. PubMed ID: 28111464
[TBL] [Abstract][Full Text] [Related]
8. Regulation of Bcl-XL by non-canonical NF-κB in the context of CD40-induced drug resistance in CLL.
Haselager M; Thijssen R; West C; Young L; Van Kampen R; Willmore E; Mackay S; Kater A; Eldering E
Cell Death Differ; 2021 May; 28(5):1658-1668. PubMed ID: 33495554
[TBL] [Abstract][Full Text] [Related]
9. c-Abl kinase inhibitors overcome CD40-mediated drug resistance in CLL: implications for therapeutic targeting of chemoresistant niches.
Hallaert DY; Jaspers A; van Noesel CJ; van Oers MH; Kater AP; Eldering E
Blood; 2008 Dec; 112(13):5141-9. PubMed ID: 18796631
[TBL] [Abstract][Full Text] [Related]
10. miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.
Sharma S; Pavlasova GM; Seda V; Cerna KA; Vojackova E; Filip D; Ondrisova L; Sandova V; Kostalova L; Zeni PF; Borsky M; Oppelt J; Liskova K; Kren L; Janikova A; Pospisilova S; Fernandes SM; Shehata M; Rassenti LZ; Jaeger U; Doubek M; Davids MS; Brown JR; Mayer J; Kipps TJ; Mraz M
Blood; 2021 May; 137(18):2481-2494. PubMed ID: 33171493
[TBL] [Abstract][Full Text] [Related]
11. Ibrutinib Plus Venetoclax for First-line Treatment of Chronic Lymphocytic Leukemia: A Nonrandomized Phase 2 Trial.
Jain N; Keating M; Thompson P; Ferrajoli A; Burger JA; Borthakur G; Takahashi K; Estrov Z; Sasaki K; Fowler N; Kadia T; Konopleva M; Alvarado Y; Yilmaz M; DiNardo C; Bose P; Ohanian M; Pemmaraju N; Jabbour E; Kanagal-Shamanna R; Patel K; Wang W; Jorgensen J; Wang SA; Garg N; Wang X; Wei C; Cruz N; Ayala A; Plunkett W; Kantarjian H; Gandhi V; Wierda WG
JAMA Oncol; 2021 Aug; 7(8):1213-1219. PubMed ID: 34110383
[TBL] [Abstract][Full Text] [Related]
12. Characterization of metabolic alterations of chronic lymphocytic leukemia in the lymph node microenvironment.
Chen Z; Simon-Molas H; Cretenet G; Valle-Argos B; Smith LD; Forconi F; Schomakers BV; van Weeghel M; Bryant DJ; van Bruggen JAC; Peters FS; Rathmell JC; van der Windt GJW; Kater AP; Packham G; Eldering E
Blood; 2022 Aug; 140(6):630-643. PubMed ID: 35486832
[TBL] [Abstract][Full Text] [Related]
13. Targeting Mcl-1 by AMG-176 During Ibrutinib and Venetoclax Therapy in Chronic Lymphocytic Leukemia.
Yi X; Jain N; Iles LR; Ayres ML; Wierda WG; Gandhi V
Front Oncol; 2022; 12():833714. PubMed ID: 35273915
[TBL] [Abstract][Full Text] [Related]
14. Dual TORK/DNA-PK inhibition blocks critical signaling pathways in chronic lymphocytic leukemia.
Thijssen R; Ter Burg J; Garrick B; van Bochove GG; Brown JR; Fernandes SM; Rodríguez MS; Michot JM; Hallek M; Eichhorst B; Reinhardt HC; Bendell J; Derks IA; van Kampen RJ; Hege K; Kersten MJ; Trowe T; Filvaroff EH; Eldering E; Kater AP
Blood; 2016 Jul; 128(4):574-83. PubMed ID: 27235137
[TBL] [Abstract][Full Text] [Related]
15. Morphologic and molecular analysis of Richter syndrome in chronic lymphocytic leukaemia patients treated with ibrutinib or venetoclax.
Gángó A; Kiss R; Farkas P; Hanna E; Demeter J; Deák B; Lévai D; Kotmayer L; Alpár D; Matolcsy A; Bödör C; Mátrai Z; Timár B
Pathology; 2022 Feb; 54(1):95-103. PubMed ID: 34332791
[TBL] [Abstract][Full Text] [Related]
16. Venetoclax-resistant CLL cells show a highly activated and proliferative phenotype.
Elias EE; Sarapura Martinez VJ; Amondarain M; Colado A; Cordini G; Bezares RF; Fernandez Grecco H; Custidiano MDR; Sánchez Ávalos JC; Garate G; Pavlovsky MA; Borge M; Giordano M; Gamberale R
Cancer Immunol Immunother; 2022 Apr; 71(4):979-987. PubMed ID: 34467417
[TBL] [Abstract][Full Text] [Related]
17. Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial.
Kater AP; Levin MD; Dubois J; Kersting S; Enggaard L; Veldhuis GJ; Mous R; Mellink CHM; van der Kevie-Kersemaekers AF; Dobber JA; Poulsen CB; Frederiksen H; Janssens A; Schjødt I; Dompeling EC; Ranti J; Brieghel C; Mattsson M; Bellido M; Tran HTT; Nasserinejad K; Niemann CU
Lancet Oncol; 2022 Jun; 23(6):818-828. PubMed ID: 35654052
[TBL] [Abstract][Full Text] [Related]
18. Waldenstrom macroglobulinemia cells devoid of BTK
Paulus A; Akhtar S; Yousaf H; Manna A; Paulus SM; Bashir Y; Caulfield TR; Kuranz-Blake M; Chitta K; Wang X; Asmann Y; Hudec R; Springer W; Ailawadhi S; Chanan-Khan A
Blood Cancer J; 2017 May; 7(5):e565. PubMed ID: 28548645
[TBL] [Abstract][Full Text] [Related]
19. MEK1/2 inhibition by binimetinib is effective as a single agent and potentiates the actions of Venetoclax and ABT-737 under conditions that mimic the chronic lymphocytic leukaemia (CLL) tumour microenvironment.
Crassini K; Shen Y; Stevenson WS; Christopherson R; Ward C; Mulligan SP; Best OG
Br J Haematol; 2018 Aug; 182(3):360-372. PubMed ID: 29767411
[TBL] [Abstract][Full Text] [Related]
20. Two Distinct Clinical Patterns of Ibrutinib-to-Venetoclax Transition in Relapsed Chronic Lymphocytic Leukemia Patients.
Ferrarini I; Gandini F; Zapparoli E; Rigo A
Curr Oncol; 2022 Apr; 29(4):2792-2797. PubMed ID: 35448201
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
